HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Raymond Lai Selected Research

Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)

12/2021BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL.
1/2021Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent.
8/2019NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma.
1/2018Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/β-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma.
11/2016A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma.
5/2016Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
7/2015STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
11/2013Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma.
4/2013The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.
2/2013Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Raymond Lai Research Topics

Disease

94Neoplasms (Cancer)
01/2022 - 01/2002
36Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
12/2021 - 09/2002
20Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
08/2013 - 12/2002
19Lymphoma (Lymphomas)
01/2021 - 09/2002
18Breast Neoplasms (Breast Cancer)
02/2021 - 08/2006
14Carcinogenesis
06/2018 - 10/2005
7Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2011 - 12/2002
6Pancreatic Neoplasms (Pancreatic Cancer)
11/2016 - 10/2004
6Carcinoma (Carcinomatosis)
01/2014 - 06/2005
5Genetic Translocation (Chromosomal Translocation)
12/2021 - 10/2007
5Melanoma (Melanoma, Malignant)
01/2018 - 01/2008
5Leukemia
11/2012 - 06/2005
4Multiple Myeloma
02/2019 - 02/2008
4Hypoxia (Hypoxemia)
12/2018 - 04/2013
4Papillary Thyroid Cancer
10/2016 - 07/2012
4Esophageal Squamous Cell Carcinoma
02/2016 - 02/2014
4Neoplasm Metastasis (Metastasis)
08/2015 - 07/2012
4T-Cell Lymphoma (Lymphoma, T Cell)
11/2013 - 09/2002
4B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
11/2008 - 09/2002
3B-Cell Lymphoma (Lymphoma, B Cell)
11/2019 - 09/2007
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2018 - 12/2005
3Lymphatic Metastasis
01/2014 - 07/2012
3Adenocarcinoma
11/2010 - 10/2004
2Mycosis Fungoides
11/2021 - 09/2002
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
10/2014 - 01/2014
2Hematologic Neoplasms (Hematological Malignancy)
08/2009 - 01/2002
2Colorectal Neoplasms (Colorectal Cancer)
07/2009 - 10/2007
2Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2007 - 09/2006

Drug/Important Bio-Agent (IBA)

45Proteins (Proteins, Gene)FDA Link
02/2021 - 09/2002
32Anaplastic Lymphoma KinaseIBA
12/2021 - 09/2002
10Biological ProductsIBA
10/2017 - 10/2005
9CateninsIBA
01/2018 - 07/2010
9GemcitabineFDA Link
11/2016 - 10/2004
9Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
05/2016 - 10/2007
9Cyclin D1IBA
01/2014 - 12/2002
8ParaffinIBA
11/2021 - 09/2003
8Doxorubicin (Adriamycin)FDA LinkGeneric
07/2015 - 01/2004
7DNA (Deoxyribonucleic Acid)IBA
10/2017 - 11/2006
7Equilibrative Nucleoside Transporter 1IBA
11/2016 - 10/2004
6Transcription Factors (Transcription Factor)IBA
07/2021 - 06/2005
6Pharmaceutical PreparationsIBA
02/2021 - 01/2008
6STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
01/2017 - 07/2004
6Tyrosine (L-Tyrosine)FDA Link
01/2012 - 09/2003
5CytokinesIBA
12/2021 - 08/2005
5Formaldehyde (Formol)FDA Link
11/2021 - 09/2003
5MicellesIBA
11/2019 - 01/2008
5Oncogene Proteins (Oncogene Protein)IBA
08/2019 - 06/2012
5Small Interfering RNA (siRNA)IBA
12/2018 - 11/2009
5Messenger RNA (mRNA)IBA
01/2015 - 10/2005
5Nucleoside Transport Proteins (Nucleoside Transporter)IBA
04/2009 - 10/2004
4CrizotinibIBA
01/2021 - 01/2016
4Rituximab (Mabthera)FDA Link
11/2019 - 11/2008
4Cisplatin (Platino)FDA LinkGeneric
10/2017 - 02/2007
4Protein Isoforms (Isoforms)IBA
10/2017 - 09/2006
4MicroRNAs (MicroRNA)IBA
01/2016 - 08/2013
4NucleosidesIBA
01/2014 - 01/2005
4TubulinIBA
12/2008 - 12/2005
3LigandsIBA
01/2022 - 07/2010
3OligonucleotidesIBA
06/2018 - 09/2006
3Estrogen ReceptorsIBA
02/2018 - 12/2010
3Silybin (Lagosa)IBA
01/2018 - 05/2016
3Paclitaxel (Taxol)FDA LinkGeneric
09/2014 - 12/2005
3SurvivinIBA
01/2014 - 05/2004
3Phosphoric Monoester Hydrolases (Phosphatases)IBA
11/2012 - 10/2006
3Phosphotransferases (Kinase)IBA
01/2012 - 09/2006
3cucurbitacin IIBA
04/2010 - 10/2006
3Tissue Inhibitor of Metalloproteinase-1IBA
08/2006 - 06/2004
3Complementary DNA (cDNA)IBA
09/2005 - 09/2003
2T-Cell Antigen Receptors (T-Cell Receptor)IBA
12/2021 - 02/2002
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
10/2021 - 10/2005
2polyethylene oxide-polycaprolactone copolymerIBA
11/2019 - 08/2008
2caprolactoneIBA
11/2019 - 01/2018
2Apoptosis Regulatory ProteinsIBA
11/2018 - 06/2003
2Interleukin-12 (IL 12)IBA
01/2017 - 08/2008
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2017 - 08/2015
2Fluorouracil (Carac)FDA LinkGeneric
02/2016 - 01/2009
2PolyethyleneimineIBA
09/2014 - 10/2011
2liposomal doxorubicin (Doxil)FDA Link
11/2013 - 06/2008
2human ERBB2 proteinIBA
10/2013 - 11/2009
2Biomarkers (Surrogate Marker)IBA
10/2013 - 10/2012
2Glycogen Synthase KinasesIBA
07/2012 - 12/2010
2Pyridinolcarbamate (P23)IBA
01/2012 - 01/2005
2Member 1 Subfamily B ATP Binding Cassette TransporterIBA
10/2011 - 02/2010
2Metalloproteases (Metalloproteinases)IBA
06/2011 - 08/2006
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
07/2010 - 08/2008
2Somatomedin Receptors (Somatomedin Receptor)IBA
06/2010 - 07/2009
2Glycogen Synthase Kinase 3 betaIBA
01/2010 - 12/2008
2Immunoglobulins (Immunoglobulin)IBA
04/2009 - 11/2006
2Bortezomib (Velcade)FDA Link
01/2009 - 04/2008
2Proteasome Endopeptidase Complex (Proteasome)IBA
01/2009 - 09/2007
2beta CateninIBA
12/2008 - 10/2006
2fludarabineIBA
11/2008 - 01/2005
2CurcuminIBA
08/2008 - 09/2005
2Vinorelbine (Navelbine)FDA LinkGeneric
06/2008 - 02/2007
2NF-kappa B (NF-kB)IBA
04/2008 - 09/2005

Therapy/Procedure

21Therapeutics
02/2021 - 09/2003
15Drug Therapy (Chemotherapy)
11/2018 - 02/2002
4Immunotherapy
01/2022 - 08/2008
2Radiotherapy
01/2015 - 04/2009
2Transplantation
11/2013 - 04/2009